"While all four generic stocks are exposed to opioid litigation, TEVA and (Endo International) ( ENDP ) appear to face more significant risk given their historical branded opioid exposure," Risinger said in a note to clients, also citing less-supportive growth forecasts and higher net leverage ratios as reasons for the downgrade.